GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials

ConclusionPooled analysis of CVOTs did not suggest any increased risk of either acute pancreatitis or pancreatic cancer with GLP-1RA treatment in T2DM patients.
Source: Endocrine - Category: Endocrinology Source Type: research

Related Links:

WEDNESDAY, Aug. 28, 2019 -- Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to a study published online Aug. 20...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 14 August 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurraySummaryBackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
CONCLUSION: Future advancements should be accompanied by the establishment of a quick diagnostic tool through the understanding of potential biomarkers of the disease and newer treatments for better control of the diseased condition. PMID: 30648511 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - Category: Endocrinology Authors: Tags: Curr Diabetes Rev Source Type: research
AbstractThree further cardiovascular (CV) outcome studies of glucose-lowering drugs (linagliptin, albiglutide and dapagliflozin) have recently been published, adding to the twelve earlier within-class studies. The linagliptin study (CARMELINA) recruited people with renal disease as well as prior CV events and confirms the overall CV safety (and other safety) of the dipeptidylpeptidase-4 (DPP4) inhibitors, with no heart failure risk associated with this agent. However, taken together with the findings from two previous studies of DPP4 inhibitors (sitagliptin and saxagliptin), the three DPP4 inhibitor CV outcome trials (CVOT...
Source: Diabetologia - Category: Endocrinology Source Type: research
ConclusioniGlarLixi has a safety profile that is consistent with that of its two active components insulin glargine and lixisenatide, with no signals for pancreatitis or thyroid C  cell tumors, and no black-box warning for iGlarLixi. There were no unexpected safety findings; iGlarLixi had beneficial effects on glycemic control, with no increased risk of hypoglycemia, despite a greater glycated hemoglobin A1c reduction. In addition, there were also fewer gastrointestinal AEs associated with iGlarLixi compared with lixisenatide alone.FundingSanofi US Inc.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
We describe a study, “Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: the DETECT study,” that seeks to address this knowledge gap. The DETECT study is a multicenter study that will examine differences in hormone and glucose excursions after a mixed meal test. The study will also create a biorepository that will be used to evaluate novel diagnostic biomarkers for differentiating these diabetes subtypes.
Source: Pancreas - Category: Gastroenterology Tags: CPDPC Conference Reports Source Type: research
The National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases initiated the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) in 2015 (the CPDPC's origin, structure, governance, and research objectives are described in another article in this journal). One of the key objectives of CPDPC is to assemble a cohort of 10,000 subjects 50 years or older with new-onset diabetes, called the NOD cohort. Using a define, enrich, and find early detection approach, the aims of the NOD study are to (a) estimate the 3-year probability of pancreatic ductal ad...
Source: Pancreas - Category: Gastroenterology Tags: CPDPC Conference Reports Source Type: research
This study is registered with ClinicalTrials.gov, number NCT02465515.FindingsPatients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-trea...
Source: The Lancet - Category: General Medicine Source Type: research
AbstractPurpose of ReviewGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of changes in blood glucose. Cardiovascular outcome trials have demonstrated safety of GLP-1 RAs but results for cardiovascular efficacy were varied. The aim of the present review is the assessment of the effects of GLP-1 RAs on cardiovascular risk factors, and major cardiovascular events.Recent FindingsUse of GLP-1 RAs was associated with relative risk reduction in ca...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Objectives Diabetes Mellitus (DM) occurs in a third of patients with chronic pancreatitis (CP). Type 3c DM (T3cDM) represents a type of DM caused by dysfunction or destruction of the islets from exocrine pancreatic disease or surgical removal. However, some individuals may have islets that are more sensitive to DM than others, resulting in early DM in some and resistance to DM in others as in Type 2 DM (T2DM). Our Aim was to evaluate patients in the North American Pancreatitis Study 2 (NAPS2) with CP and with and without DM to determine associations with known genes and environmental risk factors.
Source: Pancreatology - Category: Gastroenterology Authors: Tags: Session 9. Dieabetes and the pancreas Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pancreas | Pancreatic Cancer | Pancreatitis | Study